market leader non-invas blood-
base prenat test enter larg liquid
biopsi cancer organ transplant test market
diagnost tool
keep roll add million
balanc sheet reiter buy price target
week obtain import public signatera liquid biopsi test
breast cancer pre-announc big volum beat rais
secondari offer remain one top pick frankli
remain surpris stock trade humbl multipl given big
opportun cancer liquid biopsi like acceler revenu average-
risk nipt opportun organ transplant reject updat share count
bake secondari reiter buy rate pt
pre-announc beat file pre-announc rev
beat vs street volum y/i big
beat vs plan updat model call may
breast cancer public week announc public strong
data demonstr signatera abil detect breast cancer recurr month
ahead gold standard result publish clinic cancer research show
signatera posit identifi patient relaps sensit
median lead time month earlier imag patient
relaps signatera report zero fals posit specif show
abl detect relaps two year earlier data view spectacular natera
design custom assay detect residu breast cancer non-
metastat breast cancer patient enrol follow surgeri adjuv
therapi plasma sampl collect everi six month four year
make cancer liquid biopsi uniqu custom-build assay
uniqu cancer patient biolog estim us recurr monitor
market base us cancer survivor asp math
use monitor recurr find minim residu diseas treatment
determin therapi effect track mutat uniqu patient
compani indic greater competitor assay regardless
plan launch signatera cancer patient come week thu
opportun build market ahead similar expect launch guardant
later date cost good per cancer panel hover
believ may lower offer plan peer
strengthen balanc sheet overnight price secondari offer
could upsiz discount
tuesday close price increas compani share count share
held cash recal net cash
strateg partnership bgi march coupl rais week
estim cash solid less expect use
result pro-forma cash estim
friendli remind see upsid annual out-year revenu size
increment average-risk nipt revenu whenev gain reimburs
average-risk nipt see anoth get paid microdelet
test area believ investor forgotten expect come
addit patienc requir
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
signatera custom assay refresh signatera ruo circul tumor
dna ctdna -base assay custom patient tumor biolog use treatment
monitor assess minim residu diseas mrd signatera
methodolog use whole exom sequenc identifi uniqu clonal somat
variant individu patient tumor follow multiplex pcr ultra-deep
sequenc longitudin ctdna analysi whole blood sampl last week
announc plan launch blood-bas whole exom sequenc we
elimin need tissu identifi target mutat initi
target launch signatera lung colon breast bladder cancer
data signific
signatera clinic launch on-tap believ expect clinic
launch signatera test use cancer patient underappreci test
believ help usher paradigm chang patient test
recurr monitor residu diseas detect
we launch like big deal last week announc plan launch blood-
base whole exom sequenc we expand suit cancer offer
posit announc think open spigot
pharma trial use ffpe tumor-tissu provid add-on
cancer revenu opportun client use servic expand
oncolog databas includ we data think big deal take time
investor better understand we detect gene patient
circul tumor dna broader gene omni panel
view may abl offer we help lift
gross margin time we assay elimin need tissu
seek character somat mutat resist mutat action mutat
neoantigen tumor evolut pharma custom abl order ntra we
stand-alon add-on patient receiv ct-dna posit result
signatera ruo cancer assay requir tissu begin
pharma impact pharma client use ntra signatera ruo assay abl
run we assay leftov sampl patient blood draw patient
identifi ct-dna investig we increas
inform provid user help character tumor evolut natera cancer
offer longer limit pharma trial use tissu sampl
set launch expect small impact rev
understand contempl signatera we assay
guidanc we servic set launch remind expect
cumul contract pharma revenu ye level view
achiev given rise interest ntra expand offer oncolog
we target high-impact journal indic first mani public
accept top peer-review journal expect publish
end public seek evalu concord we
tissu plasma concord we signatera ruo believ
strong public help drive addit pharma interest beyond
likelihood stock pop around acog acog annual meet tap may
view probabl new bulletin endors average-risk
nipt believ price stock believ investor need
stock
model adjust reiter buy pt updat model bake
secondari use dilut share outstand rais prior count
share outstand price target use multipl
unchang revenu estim discount back year
discount rate use dilut share outstand
diagnost tool
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
diagnost tool
diagnost tool
diagnost tool
